Koers Rapid Therapeutic Science Laboratories, Inc.
Aandelen
RTSL
US7534312043
Farmaceutische producten
Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
0,005 USD | +25,00% | 0,00% | +21,95% |
Omzet 2021 | 0 0 | Omzet 2022 | - | Marktkapitalisatie | 5,82 mln. 5,45 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2021 | -2 mln. -1,87 mln. | Nettowinst (verlies) 2022 | -1 mln. -935K | EV/omzet 2021 | 93.978.853.933 x |
Nettoschuld 2021 | 1,79 mln. 1,68 mln. | Nettoschuld 2022 | 3,83 mln. 3,58 mln. | EV/omzet 2022 | - |
K/w-verhouding 2021 |
-16,6
x | K/w-verhouding 2022 |
-3,24
x | Werknemers | 4 |
Dividendrendement 2021 * |
-
| Dividendrendement 2022 |
-
| Vrij verhandelbaar | 75,41% |
1 dag | +25,00% | ||
Lopende maand | +47,06% | ||
1 maand | +47,06% | ||
3 maanden | +47,06% | ||
6 maanden | +6,38% | ||
Lopend jaar | +21,95% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Donal Schmidt
CEO | Chief Executive Officer | 63 | 15-11-19 |
D. Watler
DFI | Director of Finance/CFO | 75 | 15-11-19 |
Sean P. Berrier
PRN | Corporate Officer/Principal | - | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
D. Watler
DFI | Director of Finance/CFO | 75 | 15-11-19 |
Donal Schmidt
CEO | Chief Executive Officer | 63 | 15-11-19 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+21,95% | 94,93K | |
-15,13% | 4,49 mld. | |
-9,75% | 3,06 mld. | |
+2,14% | 3,04 mld. | |
-6,82% | 2,61 mld. | |
+47,87% | 1,81 mld. | |
+0,09% | 1,66 mld. | |
-7,89% | 1,63 mld. | |
-12,97% | 1,55 mld. | |
+33,40% | 1,41 mld. |